Tamiflu: payments to doctors
Payments that named Tamiflu as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.3M
- Providers
- 25
- Transactions
- 56
- Average per transaction
- $22,754
The per-transaction average — $22,754 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 25 providers the average total is $50,970, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $906,267 | 71.1% |
| Genentech USA, Inc. | $346,012 | 27.2% |
| F. Hoffmann-la Roche AG | $21,963 | 1.7% |